RT Journal Article
T1 Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.
A1 Sánchez-Cano, Daniel
A1 Callejas-Rubio, José Luis
A1 Ruiz-Villaverde, Ricardo
A1 Ríos-Fernández, Raquel
A1 Ortego-Centeno, Norberto
K1 Anticuerpos monoclonales
K1 Anticuerpos monoclonales humanizados
K1 Fragmentos Fab de inmunoglobulinas
K1 Inmunoglobulina G
K1 Glicoles de polietileno
K1 Receptores del factor de necrosis tumoral
K1 Factor de necrosis tumoral alfa
K1 Antiinflamatorios
K1 Uveítis
K1 Sarcoidosis pulmonar
K1 Uso fuera de lo indicado
AB Tumoral necrosis factor α plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a variety of disorders, such as rheumatoid arthritis, spondyloarthropatties, inflammatory bowel disease, and psoriasis. Nonetheless, theoretically, some other autoimmune disorders may benefit from these agents. Our aim is to review these off-label uses of anti-TNF blockers in three common conditions: Behçet's disease, sarcoidosis, and noninfectious uveitis. Due to the insufficient number of adequate clinical trials and consequently to their lower prevalence compared to other immune disorders, this review is mainly based on case reports and case series.
PB Hindawi Publishing Corporation
SN 0962-9351
YR 2013
FD 2013-08
LK http://hdl.handle.net/10668/1961
UL http://hdl.handle.net/10668/1961
LA en
NO Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Ríos-Fernández R, Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis. Mediators Inflamm. 2013,  2013:286857
NO Journal Article; Review;
DS RISalud
RD May 12, 2025